<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2747">
  <stage>Registered</stage>
  <submitdate>22/04/2010</submitdate>
  <approvaldate>22/04/2010</approvaldate>
  <nctid>NCT01111552</nctid>
  <trial_identification>
    <studytitle>Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)</studytitle>
    <scientifictitle>A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder</scientifictitle>
    <utrn />
    <trialacronym>ACES 256</trialacronym>
    <secondaryid>31-08-256</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Major Depressive Disorder (MDD)</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Escitalopram
Treatment: drugs - Aripiprazole
Treatment: drugs - Aripiprazole/Escitalopram combination

Active Comparator: Escitalopram monotherapy - 

Active Comparator: Aripiprazole monotherapy - 

Active Comparator: Aripiprazole/Escitalopram combination therapy - 


Treatment: drugs: Escitalopram
Escitalopram monotherapy

Treatment: drugs: Aripiprazole
Aripiprazole monotherapy

Treatment: drugs: Aripiprazole/Escitalopram combination
Aripiprazole/Escitalopram combination therapy

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - The primary efficacy endpoint is the mean change from the end of Week 8 Visit to the end of Week 14 Visit in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score.</outcome>
      <timepoint>from Week 8 to Week 14</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects with a current diagnosis of a major depressive episode. The current
             depressive episode must be = 8 weeks in duration

          -  Subjects willing to discontinue all prohibited psychotropic medication starting from
             the time of signing the informed consent and during the study period

          -  Subjects with a HAM-D17 Total Score = 18 at the Baseline Visit for the Prospective
             Treatment Phase</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Lack of prior treatment with an antidepressant during the current depressive episode

          -  Subjects who report treatment with adjunctive or monotherapy antipsychotic treatment
             during the current depressive episode.

          -  Subjects experiencing hallucinations, delusions or any psychotic symptomatology in the
             current depressive episode

          -  Subjects with epilepsy or significant history of seizure disorders

          -  Subjects with a clinically significant current diagnosis of borderline, antisocial,
             paranoid, schizoid, schizotypal or histrionic personality disorder

          -  Subjects who have received electroconvulsive therapy (ECT) in the last 10 years</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>66</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC,WA</recruitmentstate>
    <hospital> - Brisbane</hospital>
    <hospital> - Everton Park</hospital>
    <hospital> - Malvern</hospital>
    <hospital> - Melbourne</hospital>
    <hospital> - Fremantle</hospital>
    <postcode>4000 - Brisbane</postcode>
    <postcode>4053 - Everton Park</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>6959 - Fremantle</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Bourgas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Lovech</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Novi Iskar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Pleven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Rousse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Tsarev Brod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Tserova Koriya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Varna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Andhra Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Karnataka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Maharashtra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Punjab</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Tamil Nadu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Uttar Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>NCR</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucuresti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Craiova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Iasi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Targoviste</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Targu Mures</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Michalovce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Rimavska Sobota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Svidnik</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Trencin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Zlate Moravce</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This will be a multicenter, randomized, double-blind study designed to assess the efficacy,
      safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in subjects
      with MDD who have demonstrated an incomplete response to a prospective trial of Escitalopram,
      and report a treatment history for the current MDD episode of an inadequate response to at
      least one and no more than three adequate trials of an approved antidepressant other than
      Escitalopram. An inadequate response is defined as less than a 50% reduction in depressive
      symptom severity as assessed by the subject's self-report on the Massachusetts General
      Hospital Antidepressant Treatment Response Questionnaire (ATRQ) and evaluated by the
      investigator as part of the subject's medical and psychiatric history. An adequate trial is
      defined as an antidepressant treatment for at least 6 weeks duration (or at least 3 weeks for
      combination treatments) at an approved dose as specified in the ATRQ.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01111552</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>